Landau, MD, discusses results from a trial of the investigational CAR T-cell therapy NXC-201 in relapsed/refractory AL ...
Explore how genomics, comorbidities, and patient goals steer frontline CLL therapy, from fixed-duration venetoclax regimens to continuous BTK inhibitors. In an interview with Targeted Oncology at the ...
Ziftomenib combinations show promising frontline AML results, expanding trials with chemo and targeted partners; phase 3 aims ...
Regulatory approval was supported by a statistically significant improvement in 1‑year moderate‑to‑severe cGVHD‑free survival ...
Dr. Monty Pal introduces the program by outlining the evolving treatment landscape for advanced renal cell carcinoma (RCC) ...
Dr. Monty Pal discusses the historical role of the International Metastatic Renal Cell Database Consortium (IMDC) risk ...
KOMET-007 insights show ziftomenib’s manageable toxicity, low QTc risk, and easy oral dosing, supporting long-term AML ...
NCCN now recognizes personalized, tumor-informed ctDNA-MRD as a prognostic and predictive biomarker in MIBC, extending ...
Conversion from MRD negativity to positivity during maintenance is substantially lower with the quadruplet, and ...
Daniel Ermann, MD, discusses how clinical and real-world data drive his discussions with older CLL patients regarding ...
Daniel Ermann, MD, discusses his approach to treatment sequencing in patients with chronic lymphocytic leukemia who aged 80 ...
A 74-year-old man with an active lifestyle and no family history of prostate cancer presented with mild urinary hesitancy and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results